206 results about "Tumor Stem Cells" patented technology

The invention relates to the technical field of biomedical detection. By using an IncRNA chip to screen the IncRNA related to a tumor stem cell, the result shows that IncRNA-NEAT1 is highly expressed in the liver cancer stem cell and the liver cancer stem cell function can be adjusted. The invention discloses an application of the IncRNA-NEAT1 in preparation of a liver cancer diagnostic marker and an application of the IncRNA-NEAT1 in preparation of a detection reagent or a kit for diagnosing the liver cell. Moreover, the invention discloses a method for detecting the IncRNA-NEAT1 in a human serum and a kit for detecting the IncRNA-NEAT1 in the serum. Through the detection of the human serum of a liver cancer patient, the IncRNA-NEAT1 can be detected in the serum and the IncRNA-NEAT1 content in the serum of an HCC patient is obviously higher than a normal person. The kit provides a novel clinical solution for the liver cancer serological diagnosis.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

The present invention comprises a method of detecting circular tumor cells and methods of detecting, evaluating, or staging cancer in a patient, as well as a method of monitoring treatment of cancer in a patient using the claimed method. The method comprises contacting a sample with a CD45 binding agent; selecting the cells based on positive or negative CD45 staining; contacting the selected cells with a labeled nucleic acid probe, and detecting hybridized cells by fluorescence in situ hybridization; and analyzing a signal produced by the labels on the hybridized cells to detect the CTCs. In other embodiments, the method provides for directed to a method of determining the level of CTCs in a sample having blood cells from a patient by contacting a sample having blood cells from a patient, wherein the sample has not been pre-sorted into CD45-positive and CD45-negative cells.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

The invention provides a human tumor stem cell line T3A-A3, which is obtained by separation of liver cancer tissue excised in an operation of a primary hepatic carcinoma patient. The separated cells can be in long-term passage culture in vitro, can grow rapidly and retain stem cell property after more than 100 times of passage. The cell can express markers of multiple stem cells, has self-updatingcapability of stem cells and directional differentiation potentials for different tumor cells, and also has tumor property, tumorigenicity ability and metastatic ability. The invention is a powerfultool for preparing stem cell drugs for targeting tumor, due to the facts that the cells can be in long-term passage culture in vitro and retain unchanged stem cell property, and the tumorigenicity ability and metastatic ability thereof are strong in immunodeficient mice.

The present disclosure is directed to a composition for the sustained-release delivery of an active agent to a target cell of an individual. The compositions disclosed herein comprise of at least one porous particle; at least one polymer; and at least one active agent. In an embodiment, the porous particle comprises a plurality of microscale reservoirs. In an exemplary embodiment, the at least one active agent is covalently linked to the at least one polymer to form a polymer-active agent conjugate, and the polymer-active agent conjugate is contained in the plurality of microscale reservoirs of the porous particle. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual the composition described supra. Additionally, disclosed herein is a method of eliminating tumor stem cells. Furthermore, there is provided a method of circumventing multi-drug resistance in a tumor cell.

The invention provides a tumor drug-loaded microparticle preparation and a preparation method thereof. The drug-loaded microparticle preparation includes tumor stem cell apoptosis released cell vesicles and a chemotherapeutic drug wrapped in the cell vesicles as an effective component; and is prepared by mixed culture of a three-dimensional soft fibrin glue and tumor cells in a medium. The tumor drug-loaded microparticle provided by the invention is more beneficial to high enrichment in tumor tissue and deep penetration of tumors and can achieve effective uptake by common tumor cells and tumorstem cells more easily, can improve the killing power of the chemotherapeutic drug to common tumor cells and tumor stem cells, can solve the problem that common tumor cell derived drug-loaded microparticles cannot permeate to the depth parts of tumors to kill a lot of tumor stem cells, and at the same time can reduce the toxic and side effect of the chemotherapeutic drug on the body.

The invention relates to dendritic cell (DC) tumor vaccine in which a multi-medicine resistance tumor stem cell antigen composition is loaded. The antigen composition loaded in the DC tumor vaccine derives from tumor tissues, and is mainly used for tumor stem cells; and specifically, the tumor tissues are subjected to tumor stem cell primary separation and culture so as to obtain the tumor stem cells, the tumor stem cells are screened by a flow cytometry so as to obtain tumor stem cells with multi-medicine resistance, and finally full cell antigens are prepared.

The invention provides a dendritic cell carried by a tumor stem cell antigen and subjected to tolerance screening and a preparation method thereof, application of the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening in preparing anti-tumor medicament, a kit for preparing the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening, and a vaccine comprising the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening. The dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening and the medicament prepared by an immune composition of the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening can kill tumor stem cells causing tumor relapse in vivo and in vitro so as to provide possibility for overcoming the tumor tolerance and radically treating the relapse and transfer of tumor.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

The invention discloses a separating method of tumor stem cells. The separating method comprises the following steps: digesting tumor cells into single cells, then, adding the single cells into a digestive enzyme liquid to hatch for several hours; then, adding the hatched cells into a cell culture fluid containing blood serum to perform adherence growth; after the cells are adhered, transferring the adhered cells into a tumor stem cell TSC culture medium to culture; and after the cells grow all over, repeating the operation for many times, performing microsphere culture on the obtained cells to finally obtain the microspheres which are the tumor stem cells. According to the separating method of the tumor stem cells disclosed by the invention, various digestive enzymes or other physical stress conditions are combined to stimulate various tumor cells, so that TSC in different types can be stably obtained. The MuseTSC separated by the separating method disclosed by the invention has extremely strong stem characteristic and good homogeneity, and is stable, and therefore, the method can be used for enabling the obtaining of the TSC in different types to be standard, relatively simple and economical, and suitable for constructing a TSC base on a large scale to meet the working needs of the conventional tumor biomedicine basic research, the clinical research, the medicine development, and the like.

The invention relates to a tumor stem cell marker CD133-targeting polypeptide and an application thereof. A general formula of the polypeptide is CX1X2X3X4X5X6X7X8LX9. The invention further relates to a DNA fragment encoding the polypeptide, an expression vector and host cell expressing the polypeptide, and a bivalent body, a multivalent body or a pharmaceutical composition formed by the polypeptide. The polypeptide is used for detecting and targeting the tumor stem cell, and is good in specificity and sensitivity, simple in preparation method, low in cost and high in practicability. The polypeptide is applied to near-infrared fluorescence imaging to carry out high-sensitivity and high-resolution monitoring and targeted therapy on the CD133 tumor stem cell in a skin transplatation tumor. Simple, fast, economical and accurate detection means can be provided for real-time monitoring of peripheral blood CD133 expression of a patient and the correlation of the CD133 tumor stem cell in tumor recurrence, metastasis, drug tolerance and prognosis, so that the therapeutic scheme is convenient to timely adjust and novel means can be provided for improving the prognosis of patients.

The invention discloses the use of isoliquiritigenin as a medicament for preventing and treating or curing postoperative metastasis and relapse of malignant tumors, which belongs to technical field ofmedicaments. The invention discloses the use of isoliquiritigenin as a medicament for preventing and treating or curing postoperative metastasis and relapse of malignant tumors. Researches show thatthe surgical resection of primary tumors can promote tumor metastasis. At present, no ideal therapeutic method or medicament for treating malignant tumor metastasis and relapse after the resection ofthe primary tumors is available. Experiments implemented by the inventor prove that the isoliquiritigenin has a remarkable inhibition effect on the relapse and metastasis of various malignant tumors after the surgical resection of the primary tumors. Based on the effect, the isoliquiritigenin can be used in clinic prevention or treatment of the relapse and metastasis of lung cancer, liver cancer,breast cancer, colorectal cancer and other various malignant tumors after the surgical resection of the primary tumors and has the obvious advantages of high safety, low price, good patient complianceand the like. The effect of the isoliquiritigenin may be related to the inhibition of the isoliquiritigenin on the self renewal and multiplication capacity of cancer stem cells.

The invention relates to the application of circulating tumor cells undergoing epithelial-mesenchymal transformation in proliferation, drug resistance and metastasis of non-small cell lung cancer. Its advantages are as follows: the present invention establishes a method for extracting and culturing in vitro the circulating tumor cells with epithelial-mesenchymal transition, and establishes a circulating tumor cell line with related non-small cell lung cancer undergoing epithelial-mesenchymal transition. Metastasis of small cell lung cancer provides new means and methods for research. The role of this cell line in tumor proliferation, migration, invasion and drug resistance was detected through in vitro and in vivo experiments, indicating that epithelial-mesenchymal transition plays an important role in tumor growth and metastasis.